Acadia Pharmaceuticals logo

Acadia Pharmaceuticals

ACAD | NASDAQ
Chart Builder DCF Calculator
$18.67
-$0.08 (-0.43%)
At close: Nov 16, 2026, 4:00 PM ET
$18.47
-$0.20 (-1.07%)
After-hours: Nov 16, 2026, 7:30 PM ET
-0.43%

No price chart data available for 1D timeframe.

Rating

Updated: Nov 16, 2026
70.4
Fundamentals Excellent
Market Sentiment Neutral
Moat Narrow
Sector Rank #55/1021 (Top 5%)

Key Statistics

Market Data

Market Cap $3.23B
1D Range
18.60 19.44
52W Range
16.50 30.57

Valuation (TTM)

PE 8.85
PB 2.33
EV/EBITDA 15.58

Valuation (NTM)

Forward PE 24.67
Forward PEG -1.49
Price Target $33.00
Loading financial charts...

Profile

Acadia Pharmaceuticals Inc. operates as a biopharmaceutical company, primarily dedicated to discovering, developing, and commercializing small molecule therapeutics. Their core focus lies in addressin...

Sector Healthcare
Industry Biotechnology
Employees 797
IPO Date May 27, 2004
Fiscal Year January - December

Latest News

Acadia Pharmaceuticals Comments on Federal Circuit Oral Argument in NUPLAZID® Formulation Patent Appeal

7 days ago · businesswire.com

Acadia Pharmaceuticals Comments on Federal Circuit Oral Argument in NUPLAZID® Formulation Patent Appeal
Acadia Pharmaceuticals Inc. (ACAD) Q3 2026 Earnings Call Transcript

12 days ago · seekingalpha.com

Acadia Pharmaceuticals Inc. (ACAD) Q3 2026 Earnings Call Transcript
Acadia Pharmaceuticals (ACAD) Tops Q3 Earnings and Revenue Estimates

12 days ago · zacks.com

Acadia Pharmaceuticals (ACAD) Tops Q3 Earnings and Revenue Estimates
What ACADIA Pharmaceuticals (ACAD) Said on Its Q3 Earnings Call

12 days ago · marketbeat.com

What ACADIA Pharmaceuticals (ACAD) Said on Its Q3 Earnings Call
Earnings Preview: Acadia Pharmaceuticals (ACAD) Q3 Earnings Expected to Decline

20 days ago · zacks.com

Earnings Preview: Acadia Pharmaceuticals (ACAD) Q3 Earnings Expected to Decline
Can Nuplazid and Daybue Strengthen Acadia's Growth Prospects?

1 month ago · zacks.com

Can Nuplazid and Daybue Strengthen Acadia's Growth Prospects?

2 months ago · zacks.com

Acadia's Daybue Patent Allowance Extends U.S. Protection to March 2041
Acadia Pharmaceuticals Announces Allowance of U.S. Patent Covering Weight-Banded Dosing of Trofinetide, extending U.S. patent protections to March 2041

2 months ago · businesswire.com

Acadia Pharmaceuticals Announces Allowance of U.S. Patent Covering Weight-Banded Dosing of Trofinetide, extending U.S. patent protections to March 2041

2 months ago · zacks.com

ACAD Stock Down 13% as Phase II Alzheimer's Study Misses Primary Goal
ACADIA Pharmaceuticals Inc. (ACAD) Discusses Top-Line Phase II Results From RADIANT Study of Remlifanserin in Alzheimer's Disease Psychosis Transcript

2 months ago · seekingalpha.com

ACADIA Pharmaceuticals Inc. (ACAD) Discusses Top-Line Phase II Results From RADIANT Study of Remlifanserin in Alzheimer's Disease Psychosis Transcript

Earnings

Latest Earnings
Nov 4, 2026
EPS
$0.31
Beat +55.62%
REV
$342.29M
Beat +2.92%
Next Earnings
Feb 24, 2027
EPS Est
Pro
Rev Est
Pro
Earnings Details ➞

Analyst Summary

# of Analysts
16
Consensus
Buy
Price Target
$33.00
Upside
+76.75%
Buy (12)
Hold (4)
Sell (0)
Analyst Details ➞

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.